T
Turn Therapeutics Inc.
TTRXCIK 0002023016NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31
Period
FY 2025
Revenue
—
Net Income
$-3.20M
Total Assets
$12.16M
Equity
$4.69M
Shares Out
29.79M
Op. Cash Flow
$-2.60M
Business
Turn Therapeutics Inc. is a publicly listed company in Pharmaceutical Preparations, incorporated in Delaware. Common stock trades on Nasdaq under the ticker TTRX.
Auto-generated from company profile
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| General and administrative | 6 | 2 | |
| Research and development | 265,570 | 245,956 | |
| Total operating expenses | 6 | 2 | |
| Loss from operations | −6 | −2 | |
| Net gain from change in fair value of derivative liability instrument | 3 | — | |
| Gain from change in fair value of forward contract liability | 380,442 | — | |
| Amortization of deferred offering cost | −496,948 | — | |
| Interest income | 29,583 | 28,709 | |
| Other income | 176,520 | — | |
| Total other income | 3 | 28,709 | |
| NET LOSS | −3 | −2 | |
| Basic net loss per common share | −0.12 | −0.07 | |
| Diluted net loss per common share | −0.12 | −0.07 | |
| Weighted-average common shares outstanding, basic | 28 | 27 | |
| Weighted-average common shares outstanding, diluted | 28 | 27 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 5 | 872,599 | — | |
| Prepaid expenses and other current assets | 120,300 | 225,325 | — | |
| Total current assets | 5 | 1 | — | |
| Right-of-use asset | 78,620 | 120,452 | — | |
| Intangible assets, net | 922,171 | 821,931 | — | |
| Deferred offering cost, net | 6 | — | — | |
| Security deposit | 8,582 | 8,582 | — | |
| TOTAL ASSETS | 12 | 2 | — | |
| Accounts payable and accrued expenses | 3 | 667,272 | — | |
| Derivative liability instrument | 3 | — | — | |
| Current portion of operating lease liability | 46,295 | 40,660 | — | |
| Total current liabilities | 6 | 707,932 | — | |
| Operating lease liability, net of current portion | 34,081 | 80,376 | — | |
| Deferred revenue | 1 | 1 | — | |
| TOTAL LIABILITIES | 7 | 2 | — | |
| Commitments and contingencies (Note 12) | — | — | — | |
| Common Stock, $0.0001 par value, 500 million and 40 million shares authorized at December 31, 2025 and 2024, respectively; 29,445,183 and 26,845,690 shares issued at December 31, 2025 and 2024*, respectively | 2,943 | 2,684 | — | |
| Additional paid-in capital | 28 | 19 | — | |
| Subscription receivable | −1 | — | — | |
| Accumulated deficit | −22 | −19 | — | |
| Total stockholders equity (deficit) | 5 | −177,432 | 85,768 | |
| TOTAL LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT) | 12 | 2 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Depreciation and amortization | 52,746 | 47,483 | |
| Stock-based compensation expense | 419,245 | 352,833 | |
| Non-cash operating lease expense | 1,172 | 8,650 | |
| Common stock issued in exchange for services | 250,000 | — | |
| Prepaid expenses and other current assets | 105,025 | −204,505 | |
| Accounts payable and accrued expenses | 2 | 202,649 | |
| Net cash used in operating activities | −3 | −1 | |
| Purchases of intangible assets | −152,986 | −99,475 | |
| Net cash used in investing activities | −152,986 | −99,475 | |
| Proceeds from issuance of stock, net of issuance costs | 7 | 1 | |
| Net cash provided by financing activities | 7 | 1 | |
| Net increase (decrease) in cash and cash equivalents | 4 | −308,398 | |
| Right-of-use asset acquired against lease liability | — | 133,615 | |
| Common stock issued for deferred offering cost | 850,000 | — | |
| Settlement of forward contract liability for sale of shares to GEM pursuant to Initial Draw Down Notice | 380,442 | — | |
| Issuance of warrant under Share Purchase Agreement for deferred offering costs | 6 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro